Revolution Medicines Draws $250M Tranche A Loan, Declines $250M Royalty Tranche
RVMD has more than doubled off its 52-week low of $47.45.
Summary
Revolution Medicines drew $250M from its Royalty Pharma loan facility and declined an optional $250M royalty sale, preserving future revenue rights while adding debt.
Key Events · Financing and Capital Events · RVMD
-
Tranche A Loan Draw
On October 8, 2026, the company drew $250.0 million from the Royalty Pharma loan facility, paying a $5.0 million draw fee. Interest accrues at SOFR (3.50% floor) plus 5.75%, with interest-only payments until maturity on October 8, 2032.
-
Royalty Tranche Declined
The company elected not to take the optional $250 million Tranche 3 royalty purchase price, declining to deliver the Tranche 3 Notice by the October 10, 2026 deadline. As a result, Royalty Pharma will not receive the corresponding incremental revenue participation right.
-
Remaining Financing Capacity
Up to $500 million of additional loans remains available under the Loan Agreement, and up to $500 million of purchase price payments remains available under the Royalty Purchase Agreement, subject to milestones and conditions.
-
Prepayment Terms
Voluntary prepayment before the second anniversary requires a make-whole amount plus a 3.0% premium; 3.0% premium between years 2-3; 1.0% premium between years 3-6.
Analysis · RVMD · Life Sciences
Following FDA approval of Rasonque, Revolution Medicines drew $250 million from its Royalty Pharma loan facility, paying a $5 million draw fee. At the same time, the company declined an optional $250 million royalty sale, preserving future revenue rights but forgoing immediate cash. The loan carries a floating rate of SOFR (3.50% floor) plus 5.75%, maturing in 2032. This financing decision balances near-term liquidity against long-term royalty obligations.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RVMD was trading at $188.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.4B. The 52-week trading range was $47.45 to $224.31. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.